Trends in all-cause mortality among patients with chronic myeloid leukemia: A surveillance, epidemiology, and end results database analysis

Cancer

Volumn 119, Issue 14, 2013, Pages 2620-2629

  Brunner, Andrew M ^a   Campigotto, Federico ^b   Sadrzadeh, Hossein ^a   Drapkin, Benjamin J ^a   Chen, Yi Bin ^a   Neuberg, Donna S ^b   Fathi, Amir T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

age groups; bcr abl; chronic myeloid leukemia; population survival; tyrosine kinase inhibitor

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DATA BASE; ETHNICITY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREND STUDY;

AGE GROUPS; BCR-ABL; CHRONIC MYELOID LEUKEMIA; POPULATION SURVIVAL; TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84879619643     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28106     Document Type: Article

References (35)

1. De Klein A, Van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982; 300: 765-767.
2. Schaefer-Rego K, Dudek H, Popenoe D, et al. CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood. 1987; 70: 448-455.
3. Daley GQ, Van Etten RA, Baltimore D,. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247: 824-830.
4. Xie Y, Davies SM, Xiang Y, Robison LL, Ross JA,. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer. 2003; 97: 2229-2235.
5. Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011; 29: 2514-2520.
6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 1038-1042.
7. Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 2007; 92: 101-105.
8. Breccia M, Tiribelli M, Alimena G,. Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol. 2012; 84: 93-100.
9. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8: 935-942.
10. Brenner H, Gondos A, Pulte D,. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008; 93: 1544-1549.
11. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
12. Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011; 117: 5591-5599.
13. Rousselot P, Cony-Makhoul P, Nicolini F, et al. French Intergroup for Chronic Myelogenous Leukemia (Fi-LMC). Long-term safety and efficacy of imatinib mesylate (Gleevec) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study. Am J Hematol. 2013; 88: 1-4.
14. Pulte D, Gondos A, Redaniel MT, Brenner H,. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011; 16: 663-671.
15. Layde PM, Broste SK, Desbiens N, et al. Generalizability of clinical studies conducted at tertiary care medical centers: a population-based analysis. J Clin Epidemiol. 1996; 49: 835-841.
16. Begg CB, Engstrom PF,. Eligibility and extrapolation in cancer clinical trials. J Clin Oncol. 1987; 5: 962-968.
17. Wiggins CL, Harlan LC, Nelson HE, et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med. 2010; 123: 764.e1-764.e9.
18. Seiter K,. Considerations in the management of elderly patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012; 12: 12-19.
19. National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2009), released April 2012, based on the November 2011 submission. 2012. Available at: www.seer.cancer.gov. Accessed October 16, 2012.
20. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
21. Percy C, Fritz A, Jack A, et al. eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
22. Susman E,. New NCCN CML guidelines incorporate use of imatinib. Oncol Times. 2002; 24: 54-55.
23. Arias E,. United States life tables, 2000. Natl Vital Stat Rep. 2002; 51: 1-39.
24. United States Census Bureau. Census 2000 Gateway. Available at: http://www.census.gov/main/www/cen2000.html. Accessed October 21, 2012.
25. United States Department of Agriculture Economic Research Service. 2003 Rural-Urban Continuum Codes. Available at: http://www.ers.usda.gov/data- products/rural-urban-continuum-codes.aspx. Accessed November 16, 2012.
26. Henson DE, Ries LA,. The relative survival rate. Cancer. 1995; 76: 1687-1688.
27. Kantarjian HM, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985; 66: 1326-1335.
28. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998; 90: 850-859.
29. Kantarjian H, O'Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012; 119: 1981-1987.
30. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003; 98: 1105-1113.
31. Latagliata R, Breccia M, Carmosino I, et al. "Real-life" results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010; 34: 1472-1475.
32. Baker KS, Davies SM, Majhail NS, et al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15: 1543-1554.
33. Majhail NS, Nayyar S, Santibanez MEB, Murphy EA, Denzen EM,. Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant. 2012; 47: 1385-1390.
34. Berger U, Maywald O, Pfirrmann M, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005; 19: 984-989.
35. Surveillance, Epidemiology, and End Results (SEER) Program. Population Characteristics: Characteristics of the SEER Population Compared with the Total United States Population. Available at: http://seer.cancer.gov/registries/ characteristics.html. Accessed October 21, 2012.